Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Notes Payables (2022 - 2023)

Supernus Pharmaceuticals (SUPN) has disclosed Notes Payables for 2 consecutive years, with $402.5 million as the latest value for Q1 2023.

On a quarterly basis, Notes Payables changed N/A to $402.5 million in Q1 2023 year-over-year; TTM through Mar 2023 was $402.5 million, a N/A change, with the full-year FY2022 number at $402.0 million, changed N/A from a year prior.
Notes Payables was $402.5 million for Q1 2023 at Supernus Pharmaceuticals, roughly flat from $402.0 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $402.5 million in Q1 2023 to a low of $402.0 million in Q4 2022.